The Marathon Pharma Group (part of the Marathon Group investment company) has signed an agreement to acquire a controlling interest in LLC "Fort" biopharmaceutical company (part of Naсimbio, Rostec State Corporation). The transaction will be closed by year's end. The signing took place today at the Adam Smith Institute's Russian Pharmaceutical Forum.
The Fort plant is a major producer of influenza vaccines. By end 2017 it is due to supply around 18 million vaccination doses for the national inoculation program. "We have come a long way since we opened three years ago, and Fort is now a major player on the vaccines market," LLC "Fort" co-owner Anton Katlinsky says. "The arrival of a strategic investor is a new milestone in our development. Along with our business partners, we plan to turn the groundwork done by our team into reality, expand our product portfolio, and introduce technologies that are unique for Russia." The plant's 2017 earnings are expected to exceed RUB 2.2 billion.
The plant's acquisition dovetails with the development strategy for Marathon Pharma's production division, of which OJSC "Sintez", CJSC "Biocom", and LLC "Bentus Laboratories" are already part. "We plan to grow the product portfolio of this asset and harness the synergies that will be created with other companies in our production division," Marathon Group Investment Company President Alexander Vinokurov said.
Marathon Pharma Chief Operations Officer Igor Krylov and LLC "Fort" founder Anton Katlinsky signed the documents in the presence of National Immunobiological Company (Nacimbio) CEO Mariam Khubieva. Nacimbio, a Rostec subsidiary, is one of the major shareholders of the Fort biopharmaceutical company, and its blocking stake – a 25% plus one share – will remain the same.
Rostec State Corporation President Sergey Chemezov welcomes Fort's gaining of a strategic investor that is actively developing the Russian pharmaceutical market. "The company's operations play an important part in solving the problem of import substitution in the most crucial healthcare areas," Sergey Chemezov says. "Gaining an industry-specialized strategic investor will stimulate the company's further development. Fort is Rostec's second joint project, after OJSC "Sintez", with the team of Alexander Vinokurov, who has proved to be an effective partner. In 2016 Sintez improved its financial performance, doubling its net profits."